Wells Fargo & Company Vera Therapeutics, Inc. Call Options Transaction History
Wells Fargo & Company
- $434 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding VERA
# of Institutions
184Shares Held
55.1MCall Options Held
134KPut Options Held
156K-
Avoro Capital Advisors LLC New York, NY4.31MShares$208 Million2.87% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.94MShares$190 Million0.02% of portfolio
-
Black Rock Inc. New York, NY3.34MShares$161 Million0.0% of portfolio
-
Abingworth LLP London, X02.96MShares$143 Million19.0% of portfolio
-
Sofinnova Investments, Inc. Menlo Park, CA2.79MShares$135 Million11.68% of portfolio
About Vera Therapeutics, Inc.
- Ticker VERA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 27,042,300
- Market Cap $1.31B
- Description
- Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with ...